Jennifer Ruddock | Senior Vice President-Investor Relations |
Howard Robin | President and Chief Executive Officer |
Gil Labrucherie | Chief Financial Officer |
Jonathan Zalevsky | Chief Scientific Officer |
Mary Tagliaferri | Chief Medical Officer |
Chris Shibutani | Cowen |
Jessica Fye | JPMorgan |
Andy Hsieh | William Blair |
Tyler Van Buren | Piper Jaffray |
Difei Yang | Mizuho Securities |
Bert Hazlett | BTIG |
Corey Davis | Seaport Global |
Good day, ladies and gentlemen. And welcome to the Nektar Therapeutics Q2 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will be given at that time. [Operator Instructions] As a reminder, this conference call maybe recorded.